← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Stemsynergy Therapeutics, Inc.
Miami, FL
$15,204,886
Total funding
14
Grants
Funding over time
peak $2.4M · FY2010–24$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$15,204,886 · 14
By mechanism
R44$12,730,485 · 5
R43$2,249,410 · 8
R41$224,991 · 1
Investigators at Stemsynergy Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)$1,375,997
R44 · FY2019 · CA
Development of Wnt Pathway Inhibitors for Colorectal Cancer$1,099,566
R44 · FY2012 · CA
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents$1,060,173
R44 · FY2024 · CA
Development of Notch1-selective Small Molecule Inhibitor for the Treatment of Cancer$1,030,992
R44 · FY2022 · CA
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER$1,000,000
R44 · FY2017 · CA
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER$999,998
R44 · FY2018 · CA
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER$999,981
R44 · FY2019 · CA
Development of Notch1-selective Small Molecule Inhibitor for the Treatment of Cancer$945,599
R44 · FY2021 · CA
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents$939,827
R44 · FY2023 · CA
Development of a WNT Inhibitor for Advanced Stage Lung Cancer$907,344
R44 · FY2015 · CA
Development of Wnt Pathway Inhibitors for Colorectal Cancer$859,094
R44 · FY2013 · CA
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)$621,402
R44 · FY2020 · CA
Development of a WNT Inhibitor for Advanced Stage Lung Cancer$592,630
R44 · FY2014 · CA
Small Molecule N-myc Degraders as Novel Cancer Therapeutic Agents$399,999
R43 · FY2022 · CA
Small Molecule Inhibitors of Notch Activation Complex Kinase (NACK) as Novel Cancer Therapeutic Agents$399,999
R43 · FY2020 · CA
Development of an Oral WNT inhibitor$299,999
R43 · FY2018 · CA
Development of Notch Pathway Specific Inhibitors as Targeted Therapeutics for Cancer$299,994
R43 · FY2018 · CA
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)$297,882
R44 · FY2018 · CA
Targeting stem cell populations in lung cancer by modulating the Wnt and p53 path$259,451
R43 · FY2012 · CA
Development of a WNT Inhibitor for Regenerative Healing of Burn Injuries$225,000
R43 · FY2016 · GM